125797-09-3

Basic information

• Product Name: 1-(2-BROMOETHOXY)-3-ETHYLBENZENE
• Synonyms: Benzene, 1-(2-bromoethoxy)-3-ethyl-
• CAS NO: 125797-09-3
• Molecular Formula: C₁₀H₁₃BrO
• Molecular Weight: 229.1136
• Mol File: 125797-09-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 278.7°Cat760mmHg
• Flash Point: 110.3°C
• Appearance: /
• Density: 1.302g/cm³
• Vapor Pressure: 0.00712mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-3-ETHYLBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-3-ETHYLBENZENE(125797-09-3)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-3-ETHYLBENZENE(125797-09-3)

Safety Data

• Hazardous Substances Data: 125797-09-3(Hazardous Substances Data)

Usage

General Description

1-(2-Bromoethoxy)-3-ethylbenzene, also known as 2-Bromoethyl ethylbenzene, is a chemical compound consisting of a benzene ring with an ethyl group and a bromoethoxy group attached. It is commonly used in the synthesis of pharmaceuticals and other organic compounds. This chemical has a wide range of applications, including as a reagent in organic chemistry reactions and in the production of various commercial products. Its unique structure and properties make it a valuable building block for the creation of complex organic molecules. However, it is important to handle this compound with care as it is a potentially hazardous chemical that can cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C10H13BrO/c1-2-9-4-3-5-10(8-9)12-7-6-11/h3-5,8H,2,6-7H2,1H3

Upstream product

• 620-17-7 3-ethylphenol 
• 106-93-4 ethylene dibromide 

Relevant articles and documents

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

We report the synthesis of new compounds 4-35 based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3. The synthesized compounds were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR. Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro. Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy) ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (K i = 2.3 nM; EC50 = 19 nM). Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ～ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM). Interestingly, 19 (3 mg/kg, ip, and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635. Thus, the new 5-HT1AR agonist identified in this work, 19, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.